Lung failure therapies

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD.

Medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using medos products. Upon the acquisition of Medos by novalung's owners the Medos blood pump technology allowed to create both iLA activve and i-cor synchronized cardiac assist for Xenios' state-of-the-art minimally invasive therapy portfolio.

Still drawing? Don‘t miss tubing set configuration!
The Xenios tubing set configurator guides you through the process of creating your own individual Medos tubing
set.

Synchronized Cardiac Assist closes the gap between physiology and mechanical circulatory support

Although significant technical advances of extracorporeal life support (ECLS) systems have been made, the morbidity and mortality rates in patients requiring ECLS are still high, thus there is still a need for effective mechanical cardiac assist.

The novel i-cor Synchronized Cardiac Assist is a small extracorporeal pump that is synchronized to the heart beat (the ECG) so that augmentation of cardiac output with well-oxygenated blood occurs during diastole and does not represent an increased afterload on the heart during systole.

The technology designed to offer physiological circulatory support is expected to increase cardiac output, stabilize the vital signs and reduce the manifestations of cardiogenic shock.

In those patients receiving i-cor Synchronized Cardiac Assist during high risk PCI procedures, it is expected that myocardial tissue will be preserved and cardiac function protected by the device.

The anticipated benefits of using the i-cor device include the advantage of pulsatile perfusion in terms of surplus hemodynamic energy, achievable at lower mean flow and improved coronary perfusion.